| Literature DB >> 33359617 |
Xichun Qin1, Yeqing Zhou1, Yuzhuo Wang1, Ziyao Wang2, Yun Wang2, Jiali Chen1, Lidong Zhu1, Xiaoyu Quan1, Zhiwei Liu3, Hao Zhang1, Liqun Jiang4, Hongyan Dong5, Zhongming Zhang6.
Abstract
In the treatment of heart disease, strategies for the targeted delivery of protein therapeutics to the heart by inhalation are still immature. Perfluorocarbons (PFCs) are inert chemicals with good biocompatibility, and unique physico-chemical properties that have recently led to their applications in numerous fields. In this study, we combined the advantages of protein-phospholipid complexes and PFC emulsions and then synthesized protein-loaded PFC nanoemulsions (PNEs) to test whether, after inhalation, these nanoemulsions could deliver therapeutic proteins to the heart. After preparing protein-phospholipid complexes by lyophilization, we obtained PNEs by extrusion. The particle size and surface charge of PNEs were about 140 nm and -50 mV, respectively. In vitro results showed that the PNEs had a fine particle fraction of 35% and exhibited sustained protein release. Translocation studies were done using three types of pulmonary epithelial cells, and ~7% translocation was observed in the Calu-3 cell line. Further, they were easily absorbed by cells and had therapeutic effects in culture. In vivo results showed that the PNEs successfully delivered proteins to the myocardial tissue of rats and reduced ischemic myocardial injury caused by acute myocardial infarction (AMI). This study suggests that inhalation of PNEs is a new potential strategy to deliver proteins to cardiac tissues for treating heart diseases.Entities:
Keywords: Drug delivery; Heart target; Inhalation; Nanoemulsion; PFC; Protein-phospholipid complexes
Mesh:
Substances:
Year: 2020 PMID: 33359617 DOI: 10.1016/j.ejps.2020.105690
Source DB: PubMed Journal: Eur J Pharm Sci ISSN: 0928-0987 Impact factor: 4.384